Regarding the use of bivariate vaccines as initial schedule and periodicity of boosters: 1) CoNaIn recommends the use of bivariate vaccines as booster doses while recognizing that in the current situation monovalent vaccine can continue to be used for this purpose. 2) In the event that The National Administration of Drugs, Food and Medical Technology approves their use as a primary schedule, CoNaIn will recommend their use for that purpose. 3) Regarding the periodicity, CoNaIn recommends that the boosters be biannual, tending in the future to an annual periodicity. Regarding HPV vaccination schedule: 1) A one-dose schedule up to 20 years of age and two doses up to 26 years of age is recommended, which would facilitate the schedule and coverage with strict
epidemiological and vaccination coverage surveillance. 2) The nonvalent vaccine can be used when available, but the quadrivalent vaccine can continue to be used until then, since studies show no difference in immune response. 3) Incorporate as a target population people with Systemic Lupus Erythematosus, Juvenile Rheumatoid Arthritis, Inflammatory Bowel Disease, dermatomyositis, and other autoimmune diseases in plan to receive immunosuppressive drugs. 4) Communication of the strategy should be emphasized.